Larimar Therapeutics (LRMR) EV to EBIT (2020 - 2026)
Larimar Therapeutics' (LRMR) quarterly EV to EBIT came in at 4.67 in Q2 2026, down 179.29% on a YoY basis from 5.9 in Q2 2025, and down 66.51% quarter-over-quarter from 2.81 in Q4 2025.
Powered by 
Analysis
Larimar Therapeutics (LRMR) EV to EBIT (2020 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has reported EV to EBIT for 7 consecutive years, with 4.67 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EV to EBIT fell 179.29% year-over-year to 4.67; the trailing twelve-month figure through Jun 2026 stood at 0.91 (down 113.29% YoY), and the FY2025 full-year result was 1.04, down 49.11% from the prior year.
- EV to EBIT eased to 4.67 in Q2 2026 per LRMR's latest filing, from 2.81 in the prior quarter.
- Across five years, EV to EBIT topped out at 6.29 in Q3 2022 and bottomed at 15.35 in Q1 2024.
- Historically, EV to EBIT has averaged 4.14 across 5 years, with a median of 2.81 in 2025.
- The sharpest annual moves came in 2022 and 2023: EV to EBIT surged 187.95% in 2022, then sank 977.14% in 2023.
- Over 5 years, EV to EBIT stood at 1.15 in 2022, then tumbled by 792.16% to 7.98 in 2023, then soared by 74.56% to 2.03 in 2024, then slumped by 38.33% to 2.81 in 2025, then plunged by 66.51% to 4.67 in 2026.
- According to Business Quant data, EV to EBIT over the past three periods registered 4.67, 2.81, and 2.04 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.67 |
| Dec 31, 2025 | -2.81 |
| Sep 30, 2025 | -2.04 |
| Jun 30, 2025 | -1.67 |
| Mar 31, 2025 | 0.64 |
| Dec 31, 2024 | -2.03 |
| Sep 30, 2024 | -11.73 |
| Jun 30, 2024 | -9.61 |
| Mar 31, 2024 | -15.35 |
| Dec 31, 2023 | -7.98 |
| Sep 30, 2023 | -7.53 |
| Jun 30, 2023 | -3.25 |
| Mar 31, 2023 | -11.06 |
| Dec 31, 2022 | 1.15 |
| Sep 30, 2022 | 6.29 |
| Jun 30, 2022 | 2.33 |
| Mar 31, 2022 | -1.03 |
| Dec 31, 2021 | -13.32 |
| Sep 30, 2021 | -7.15 |
| Jun 30, 2021 | -6.40 |